# Clinical Cases: Diabetes Mellitus - Management

## Case 1: Type 2 Diabetes - Initiating and Intensifying Therapy

### Patient Demographics
- **Age:** 54 years
- **Sex:** Male
- **Occupation:** Office manager

### Chief Complaint
"My blood sugars are still high despite taking my diabetes pill."

### History of Present Illness
A 54-year-old man with type 2 diabetes diagnosed 3 years ago presents for diabetes management. He was initially started on metformin 500 mg twice daily, which was increased to 1000 mg twice daily 1 year ago. Despite adherence to medication and attempts at lifestyle modification, his HbA1c has progressively risen from 7.2% at diagnosis to 8.8% at his last visit 3 months ago. He reports polyuria and polydipsia, fatigue, and recent weight gain of 8 pounds. He also has hypertension (on lisinopril), hyperlipidemia (on atorvastatin), and obesity (BMI 34). He had a myocardial infarction 2 years ago with stent placement. His father died of a heart attack at 58, and his mother has diabetes and chronic kidney disease.

### Physical Examination
- **Vital Signs:** BP 138/86 mmHg, HR 76 bpm, Weight 238 lbs, BMI 34
- **General:** Obese, well-appearing
- **Cardiovascular:** Regular rhythm, no murmurs
- **Abdomen:** Obese, no organomegaly
- **Extremities:** No edema, intact sensation to monofilament
- **Skin:** Acanthosis nigricans at neck

### Workup
- **Laboratory Studies:**
  - HbA1c: 9.2% (above goal despite current therapy)
  - Fasting glucose: 218 mg/dL
  - Creatinine: 1.2 mg/dL, eGFR: 72 mL/min/1.73m²
  - UACR (urine albumin-to-creatinine ratio): 85 mg/g (moderately increased)
  - LDL: 78 mg/dL (on statin)
  - Triglycerides: 185 mg/dL
- **Recent Studies:**
  - Echocardiogram: EF 50%, no wall motion abnormalities
  - Dilated eye exam: Mild non-proliferative diabetic retinopathy

### Assessment
- Type 2 diabetes, suboptimally controlled (HbA1c 9.2%, goal <7%)
- Established atherosclerotic cardiovascular disease (prior MI)
- Early diabetic nephropathy (moderately increased albuminuria)
- Mild non-proliferative diabetic retinopathy
- Obesity

### Treatment Plan

**AGENT SELECTION BASED ON COMORBIDITIES:**

Given this patient's profile:
- **Established ASCVD** → GLP-1 RA with proven CV benefit (semaglutide, liraglutide, dulaglutide)
- **CKD/Albuminuria** → SGLT2 inhibitor with proven renal benefit (empagliflozin, dapagliflozin)
- **Obesity** → Both GLP-1 RA and SGLT2i promote weight loss
- **Need to avoid hypoglycemia** → GLP-1 RA and SGLT2i have low hypoglycemia risk

**RECOMMENDED REGIMEN:**
1. **Continue metformin** 1000 mg BID (foundation therapy)
2. **Add GLP-1 receptor agonist** (first-line add-on given ASCVD):
   - Semaglutide 0.25 mg weekly x 4 weeks, then 0.5 mg weekly, titrate to 1 mg weekly
   - Expected HbA1c reduction: 1.0-1.5%
   - Additional benefits: Weight loss (8-15 lbs), CV mortality reduction
3. **Add SGLT2 inhibitor** (for CKD/albuminuria protection):
   - Empagliflozin 10 mg daily
   - Expected HbA1c reduction: 0.5-0.8%
   - Additional benefits: Reduces CKD progression, CV protection, modest weight loss

**IF HbA1c REMAINS >8% AFTER 3 MONTHS:**
- Consider adding basal insulin (glargine 10 units at bedtime, titrate by 2 units every 3 days to fasting glucose goal)

**COMPREHENSIVE DIABETES CARE:**
1. **Glycemic target:** HbA1c <7% (individualized)
2. **Blood pressure:** Target <130/80 mmHg (continue ACE inhibitor for renal protection)
3. **Lipids:** Continue statin, LDL goal <70 mg/dL (ASCVD)
4. **Aspirin:** Continue 81 mg daily (secondary prevention)
5. **Renal protection:** ACEi + SGLT2i (slow CKD progression)
6. **Eye care:** Annual dilated exam (more frequent if retinopathy progresses)
7. **Foot care:** Annual comprehensive foot exam, patient education

**PATIENT EDUCATION:**
- GLP-1 RA: Nausea common initially (take with meals, will improve); inject weekly
- SGLT2i: Genital hygiene (increased yeast infections); signs of euglycemic DKA
- Lifestyle: Continued emphasis on diet and exercise

### Follow-up Plan
- HbA1c in 3 months
- Renal function and UACR in 3 months
- If HbA1c improved but still >7%, continue current regimen
- If HbA1c still >8%, add basal insulin

### Clinical Pearl
Current diabetes treatment guidelines emphasize a patient-centered approach that considers comorbidities rather than a stepwise escalation based solely on HbA1c. For patients with established ASCVD, GLP-1 receptor agonists with proven cardiovascular benefit (semaglutide, liraglutide, dulaglutide) are preferred regardless of HbA1c. For patients with CKD or heart failure, SGLT2 inhibitors are preferred for their organ-protective effects independent of glucose lowering. The combination of GLP-1 RA + SGLT2i is increasingly used in patients with both ASCVD and CKD, providing complementary cardiorenal protection. Weight loss with these agents also improves insulin sensitivity and may reduce the need for additional therapy.

### Clinical Image
![Insulin Delivery Devices](case_01_image.jpg)

*Image showing insulin delivery devices including insulin syringes and pens used for subcutaneous insulin administration in diabetes management.*

**Image Source:** Wikimedia Commons - "Insulin syringe and pen"
**License:** CC BY-SA 4.0
**URL:** https://commons.wikimedia.org/wiki/File:Insulin_syringe_and_pen.jpg

---

## Case 2: Severe Hypoglycemia in a Patient with Type 1 Diabetes

### Patient Demographics
- **Age:** 34 years
- **Sex:** Female
- **Occupation:** Registered nurse (works night shifts)

### Chief Complaint
"My husband found me unresponsive this morning."

### History of Present Illness
A 34-year-old woman with type 1 diabetes for 20 years is brought to the emergency department by her husband, who found her unresponsive in bed at 7 AM. She appeared pale and diaphoretic, and he was unable to wake her despite shaking. He administered intranasal glucagon which he had been taught to use, and she gradually became responsive over 15-20 minutes. By the time of ED arrival, she is alert but confused about the morning's events. She recalls going to bed at 11 PM after her usual evening insulin dose but does not remember waking up. Her husband reports she has had several "low blood sugar episodes" over the past few months, including one where she became confused during a family dinner. She admits she often does not feel her low blood sugars coming on anymore.

### Medical History
- Type 1 diabetes x 20 years
- Hypothyroidism
- Recurrent hypoglycemia (several episodes in past 3 months)
- Prior severe hypoglycemia requiring paramedic assistance 6 months ago

### Current Diabetes Regimen
- Insulin glargine 22 units at bedtime (basal)
- Insulin lispro per sliding scale and carb counting (bolus)
- Estimates total daily dose ~45 units
- Self-monitoring blood glucose 3-4 times daily
- Does not use continuous glucose monitoring

### Physical Examination (In ED)
- **Vital Signs:** BP 128/78 mmHg, HR 88 bpm, Glucose (POC): 142 mg/dL (after glucagon)
- **General:** Alert, oriented x 3, mild residual confusion
- **Cardiovascular:** Regular rhythm, no murmurs
- **Neurologic:** Intact, mild tremor resolving
- **Skin:** Diaphoresis resolved

### Workup
- **Laboratory Studies:**
  - Glucose (venous): 138 mg/dL (after glucagon)
  - HbA1c: 6.4% (below typical target - suggests frequent lows)
  - C-peptide: <0.1 ng/mL (confirms type 1, no endogenous insulin)
  - BMP: Normal
  - TSH: 2.1 mIU/L (on levothyroxine)
- **Patient's Glucose Log Review:**
  - Multiple readings <70 mg/dL over past month
  - Several readings <54 mg/dL
  - No symptoms documented with many low readings

### Diagnosis
**Severe hypoglycemia (Level 3)** with **hypoglycemia unawareness** in type 1 diabetes

### Hypoglycemia Classification

| Level | Definition | This Patient |
|-------|------------|--------------|
| Level 1 | Glucose <70 mg/dL (alert value) | Multiple episodes |
| Level 2 | Glucose <54 mg/dL (clinically significant) | Several episodes |
| Level 3 | Severe, requires assistance | Today's event |

### Contributing Factors
1. **Hypoglycemia unawareness:** Loss of autonomic warning symptoms from recurrent hypoglycemia
2. **HbA1c 6.4%:** Below target, indicating frequent hypoglycemia
3. **Shift work:** Irregular eating and sleeping patterns
4. **Fixed basal insulin dose:** May be excessive for her overnight needs
5. **No CGM:** Lacks real-time glucose monitoring and predictive alerts

### Treatment

**ACUTE MANAGEMENT (Already provided):**
- Intranasal glucagon by husband (appropriate)
- Now euglycemic - oral carbohydrates to prevent recurrence

**HYPOGLYCEMIA UNAWARENESS REVERSAL:**
1. **Strict hypoglycemia avoidance for 2-3 weeks:**
   - Raise glycemic targets temporarily
   - Target fasting glucose 100-150 mg/dL
   - Avoid ALL hypoglycemia
   - Autonomic awareness often returns after 2-3 weeks without lows

**INSULIN REGIMEN ADJUSTMENTS:**
1. **Reduce basal insulin:** Decrease glargine from 22 to 18 units
2. **Review bolus dosing:** Consider reducing insulin-to-carb ratio
3. **Consider insulin pump:** Allows variable basal rates (lower overnight)

**CONTINUOUS GLUCOSE MONITORING (CGM) - Essential:**
1. **Recommend CGM with alerts:** (e.g., Dexcom G6, Libre 2)
2. **Benefits:**
   - Real-time glucose readings every 5 minutes
   - Predictive low glucose alerts (warns before hypoglycemia occurs)
   - Patterns identification
   - Time in range metrics
3. **Set low alert at 80 mg/dL** (higher threshold given unawareness)

**CONSIDER HYBRID CLOSED-LOOP SYSTEM:**
- Insulin pump + CGM integration
- Automatic basal adjustment based on glucose trends
- Suspend insulin delivery when glucose dropping
- Shown to reduce hypoglycemia significantly

**PATIENT AND FAMILY EDUCATION:**
1. **Glucagon availability:** Prescription for nasal glucagon (Baqsimi) or ready-to-inject (Gvoke)
2. **Husband education:** Reinforce glucagon administration technique
3. **Rule of 15:** 15g fast-acting carbs, wait 15 minutes, recheck
4. **Driving safety:** Do not drive if glucose <80 mg/dL or feeling "off"
5. **Medical alert bracelet**

**ADJUSTED GLYCEMIC TARGETS:**
- HbA1c goal: 7.0-7.5% (slightly higher to reduce hypoglycemia risk)
- Time in range goal: >70% (70-180 mg/dL)
- Time below range (<70): <4%
- Time below 54 mg/dL: <1%

### Clinical Pearl
Hypoglycemia unawareness occurs in ~25% of patients with type 1 diabetes and significantly increases the risk of severe hypoglycemia. It results from repeated hypoglycemic episodes that blunt the counter-regulatory hormone response and autonomic symptoms. The good news is that strict hypoglycemia avoidance for 2-3 weeks can often restore awareness. A HbA1c below target (especially <6.5%) in a patient with type 1 diabetes should raise suspicion for frequent hypoglycemia. Continuous glucose monitoring with predictive alerts is transformative for these patients, warning of impending lows before they occur. Hybrid closed-loop systems further reduce hypoglycemia by automatically adjusting insulin delivery. All patients with type 1 diabetes and their close contacts should have glucagon readily available and know how to use it.

### Clinical Image
![Insulin Delivery Devices](case_01_image.jpg)

*Insulin delivery devices used in diabetes management. Proper insulin technique and timing are critical to avoiding hypoglycemia, particularly in patients with type 1 diabetes.*

**Image Source:** Wikimedia Commons - "Insulin syringe and pen"
**License:** CC BY-SA 4.0
**URL:** https://commons.wikimedia.org/wiki/File:Insulin_syringe_and_pen.jpg

---